HUMAN GH (hGH) has profound lipolytic/antilipogenic actions in vivo, which result in decreased fat mass, increased lean mass, and weight loss (1–3). Studies in vitro and in vivo have indicated that this response is mediated in part by an increase inβ -adrenoceptor coupling efficiency (4), a reduction in Gi expression (5), increased activity of hormone sensitive lipase (6), and an inhibitory effect on the action of insulin (7). We have synthesized a fragment of hGH (AOD9604) that contains a lipolytic domain that may be responsible for the lipolytic action of hGH. The parent molecule, AOD9401, induces lipolysis and antilipogenesis and fat oxidation in adipose tissue in vitro (8, 9). In vivo, AOD9401 induces weight loss without affecting food intake as well as increasing lipolytic sensitivity and increasing fat oxidation with no adverse effects on insulin sensitivity (8, 10).

For example, studies have shown that people deficient in IGF-1 have an increased chance of dying from a heart attack. This is because IGF-1 prevents the death of heart cells and offers protection to heart cells when the cells are stressed, such as during a heart attack or long amount of time without oxygen. IGF-1 has a similar protective effect on brain cells.


Your body requires a minimum number of calories each day in order to maintain your current weight, called your “calorie maintenance level”. If you only ate that number of calories each day, you would never gain or lose a pound. This is the calorie count with which you will maintain your weight. Your calorie maintenance level is the number of calories your body requires to function, and these calories are burned through walking, sitting, moving, pumping your blood, breathing, digesting food – just living, basically.

If your unaccompanied goal is huge loss, it’s regularly best to skulk the act with regard to of GHRP products (GHRP-6, GHRP-2 or Hexarelin) being they gave a pink slip stimulate feel a dearth of and/or am a dealer of strength cortisol, both of which boot be counterproductive to immense burning. Ipamorelin, on the other laborer makes a great addition for it has no marching to a different drummer side chattels personal and increases GH secretion ultimately more, providing the applied force for drastic reductions in fat.


Prolonged use of intact hGH may result in negative effects on glucose metabolism, such as glucose intolerance and insulin resistance. Given that AOD9604 is a peptide fragment of the C-terminus of hGH, its effect on glucose control was monitored. OGTT testing was carried out on all patients during the screening phase as well as at various time points during the treatment period. No significant changes or obvious trends in the OGTT in any treatment group were observed, suggesting that AOD9604 supplementation does not deteriorate glucose control or induce insulin resistance. In contrast, treatment with AOD9604 seemed to have a positive effect in subjects with impaired glucose tolerance. In the 12 weeks treatment study, patients with impaired glucose tolerance supplemented with AOD9604 were less likely to develop diabetes during the study than subjects taking placebo. This hypothesis, however, has to be confirmed in a separate clinical trial. In contrast, in a recent clinical trial of hGH effects in obese women, hGH caused an increase in IGF-1 levels over a 6 month dosing period and decreased glucose tolerance in a subset of trial participants [29].

The matters under subsection 52E (1) of the Therapeutic Goods Act 1989 considered relevant by the delegate included: a) the risks and benefits of the use of a substance; b) the purposes for which a substance is to be used and the extent of use of a substance; c) the toxicity of a substance; d) the dosage, formulation, labelling, packaging and presentation of a substance; e) the potential for abuse of a substance; f) any other matters that the Secretary considers necessary to protect the public health.
The full activation of the hGH-receptor requires dimerization of two receptor molecules by one intact growth hormone molecule. The hGH has two different binding regions, site 1 and site 2, which bind in a sequential manner to two different regions of the receptor. Only if this trimer of one hGH molecule and two receptors is formed, does the subsequent signal transduction pathway become initiated [27, 28]. The hexadecapeptide AOD9604 consists only of amino acids 177-191 of hGH with an additional tyrosine residue at the N-terminus. The binding site 1 of the hGH, which is located in the fourth helix [27], is partially overlapping with the sequence of AOD9604. However, binding site 2 of hGH is completely missing in AOD9604. Therefore, it was hypothesized that AOD9604 is unable to induce dimerization and thereby activation of the receptor. This has been confirmed in previous in vitro experiments. Competition binding assays in cells transfected with the 125I-hGH receptor have shown that AOD9604 is incapable of competing with hGH for binding [20]. In a highly sensitive BaF3 cell proliferation test Heffernan et al (2001) also showed that AOD9604 did not induce cell-proliferation even in very high dosages [20].
Peptide therapy encompasses numerous different drugs with varied effects, ranging from immune modulation and tissue repair to fat loss and muscle building. Our center has seen very positive results in patients with CFS, Hashimoto’s thyroiditis, Lyme disease, and fibromyalgia, among other conditions. Ask your physician or speak to a patient representative at (877) 508-1177 to find out if peptide therapy is right for you.
As in the previous study there were no clinically relevant changes observed in safety laboratory parameters 24 hours following administration of AOD9604 or placebo. Similarly, there were no clinically relevant changes in vital signs (blood pressure, radial pulse rate and temperature) or ECGs recorded at any of the scheduled time points up to 24 hours post dose. There were no significant changes in glucose or IGF-1 levels following AOD9604 treatment compared with placebo.

I'm new to the forum and there is some great information here that I need to do more reading on. I've been taking Ipam and ModGrf 1-29 for at least 2yrs now. The first thing I noticed is that I have good quality sleep. I have difficulty sleeping and staying asleep. I take these peps 20min before I go to bed and get a good deep sleep for at least most of the night. I take them before doing my morning cardio, after my workout (afternoon) and before I go to bed. I've read if you take it before your morning cardio it releases more FFA to burn during your session. After the workout to aid in recovery. Before bed to aid in a deeper sleep. It is important when you take them. Dont eat before morning cardio...no carbs/sugary drinks...3hrs should have passed before taking another shot and do not eat before 15-20min after taking the peps. The reason (I've read) to wait these times is to take them while your insulin levels are low. High Insulin levels will minimize the pulsation of the GH. The phrase I've read is to try to keep "insulin quiet" to maximize the pulse of GH. Ipam can work by itself but if taken with ModGrf 1-29 it will magnify the GH Pulse. ModGrf is useless by itself. I've read that there is a saturation dose, so more is not better. 200mcg for each should do the job. Since synthetic GH shuts down natural production, these peps stimulate the pituitary to pulse more natural GH. To get the maximum effect of syn GH, you would also take the shot at the same time discussed above. Once again, this is what I've read and the protocol that I've followed. The results arent like AAS (nothing is!) but it is a good way to feel better since I cant take TRT. (trying to have kids) I also travel with the peps bc I value the sleep that I get from it.


These peptides are inhibitors of a protein called myostatin. Myostatin is secreted by muscle cells and acts to essentially block the development of new muscle fibers and, thus, the development of lean muscle mass. In fact, individuals who have mutations in the gene coding for this protein have significantly more muscle mass and enhanced strength. The administration of follastatin peptides can generate enhanced muscle mass and strength, and has been found especially useful in patients suffering from muscle-wasting diseases or who have difficulty gaining muscle.
Strengths of our study include the serial physiologic assessments before and after bariatric surgery. The gastric bypass procedure ensured a large degree of weight loss (≈27% mean change in BMI), while the administration of normal saline provided an acute stimulus for eliciting acute natriuretic peptide responses. Thus, we were able to compare the relative effects of weight loss and saline infusion, with each individual serving as his or her own control. This study design minimizes confounding from sources of natriuretic peptide variation that might correlate with BMI. We performed the post‐surgical assessment 6 months after surgery to ensure that acute hemodynamic changes from surgery had resolved and patients had attained most of their expected weight loss. Mitral annular early diastolic (e′) velocity at the lateral annulus has been accepted as an index of diastolic function24, 25 and we had significant improvement in e′ suggesting improvement in myocardial relaxation. Our echocardiographic findings are in accordance with the recently published meta‐analysis demonstrating benefits of bariatric surgery on diastolic function.26
From this study it appears that the β3-AR is an important contributor to the effects observed on body weight in obese mice treated with AOD9604 and hGH. To determine whether theβ 3-AR is partly responsible for this effect, we examined the effects of AOD9604 and hGH in theβ 3-KO mouse. The β3-KO mouse is not grossly obese, but female mice have increased fat depots (21) and the mice do develop late-onset obesity (Summers, R. J., personal communication). AOD9604 and hGH increased body mass and decreased BAT mass in the WT strain but had no effect in the KO animals. In WT mice, plasma glycerol was increased in response to AOD9604 and hGH treatment (4 wk). However, in the KO mice, only hGH resulted in increased levels of glycerol in the KO mice, and this effect was significantly less than that observed in the WT mice. This suggests that the regulation of the β3-AR is essential in the ability of AOD9604 and hGH to mediate chronic effects on lipolysis and fat mass reduction.
Male New Zealand white rabbits (n=32; aged 12 weeks) were used in the experiments. Animals were housed in separate metal cages at a temperature of 23°C±2°C and relative humidity of 45%±10%. The animals were allowed free access to tap water and were fed a commercial rabbit diet. Animal experiments were performed in accordance with internationally accredited guidelines and approved by laboratory’s Institutional Animal Care and Use Committee.
Both paracetamol and caffeine are regarded as being well tolerated when used at therapeutic doses and there is a low risk of serious expected or serious unexpected adverse events with these products when taken either alone or in combination. Clinical data demonstrate that paracetamol combined with caffeine significantly out performs paracetamol alone. Paracetamol/caffeine formulations are well established globally. Such formulations are marketed in over 90 countries and have been available unscheduled ranging from 14 years to 25 years. Cumulative post-marketing experience to date with the sponsor’s paracetamol/caffeine combination products is estimated to be in excess of 488 million patients and has revealed no adverse safety signals or reasons for concern with the use of this product in an open sale environment.

Mod GRF 1-29 and CJC-1295 are still being researched. As such, they are not yet medically utilized or approved. Though some firm protocols for the use of these peptides have been developed, the dosage of the compound is not yet medically confirmed. In a study conducted by researchers on 21 to 61 year-old subjects, it was found that depending on the dose, the concentrations of the growth hormone increased to up to 10 times for at least 6 days. Also, the concentration of IGF-1 increased to up to 3 times for 9 to 11 days.
Serum IGF-1 levels remained relatively constant over the dosing period with no apparent differences between treatment groups. Fasting plasma glucose and serum insulin levels remained unchanged throughout the treatment period. Furthermore, no changes in any of the OGTT parameters were observed from day 1 to day 7 of treatment. There were no study related clinically significant findings in the safety related laboratory tests, vital signs, or ECG measurements.
There were no changes in laboratory parameters or vital signs in any treatment group. There were no clinically significant abnormalities in vital signs, safety tests, or ECGs during the studies. At no time were statistically significant differences in IGF-1 levels among the treatment groups and placebo detected. The overall mean changes in IGF-1 were 1.76 nmol/L and 1.24 nmol/L after 12 and 24 weeks of treatment, respectively. There were no statistically significant differences between the treatment groups or placebo (P = 0.50844 after 12 weeks and P = 0.75754 after 24 weeks).
Metabolic has just completed Phase IIA studies in a group of 22 clinically obese, but otherwise healthy, male patients ranging in age from 22?50. The results showed that the drug was well tolerated and increased fat metabolism within two hours of administration by 25 per cent in the older group of patients. Although not the focus of the study, weight loss was also demonstrated, particularly in the older group.
I have questions about combined therapy of CJC 1295 and Ipamorelin at the same time on a daily basis for both. The compounding pharmacies do not clearly state whether the CJC is with or without DAC. If it is the CJC with DAC, which sustains elevated GH and IGF-1 for several days, would taking it nightly in conjunction with the Ipramorelin, that is suggested to be taken TID but is being recommended only once at night, be over-stimulatory? If the CJC is without DAC, why take two pepetides simultaneously ,that have similar effects? I am just not clear why taking a daily dose of CJC with Ipamorelin as a single dose is better than taking the CJC with DAC twice per week alone or take the CJC with DAC for a while then switch to the Ipamorelin for a while?
The objective of the 3rd study (METAOD003) was to assess the safety, tolerability and pharmacodynamics of single oral doses of AOD9604 in healthy, clinically obese males. 17 subjects (n = 15 completed the study), age 35 to 54 years, with a BMI ≥ 35 kg/m2 (range 35 to 56 kg/m2) subsequently received 3 increasing doses of AOD9604 (9, 27 and 54 mg) or placebo. Each dose administration was separated by a 2-week wash-out period.
200 to 300 mcg is typically the daily dosage which is recommended for the typical Ipamorelin user. It can be taken anytime during the day but is advisable to be used in the morning, as it will help you achieve the best results in such cases. Regardless of when you start your dosage, it is important to ensure you are taking it at the same time each day. And, for new users, it is best to stick to a one-a-day cycle.
Django Nathan, a medical doctor with a degree in molecular biology and genetics, takes peptides because of his busy lifestyle: "Quite a few doctors I know are using them because they have so many beneficial effects and so few side effects. We're not elite athletes – we live rushed lives that can involve 70 hour weeks so staying fit and getting good sleep is essential – and peptides aid that."
×